Investment in UK university spinouts reached £1.56bn in the first half of 2026, even as first-time equity funding fell by more than two-thirds, revealing a growing gap between the largest established science businesses and companies seeking their first external investors.
The latest study from IP Group‘s Parkwalk operation and data provider Beauhurst records the second-highest half-year funding total of the past decade. Investment was 38.2% above the second half of 2025 and close to the £1.58bn peak recorded in the first half of 2021.
However, £709m of the latest total came from only four investment rounds. Three were associated with advanced computing businesses, including Quantum Motion, Oxford Quantum Circuits and Fractile. Oxford Quantum Circuits secured a £260m round, the largest of the six-month period.
The aggregate funding total obscures a narrower entry point into the investment market. First-time equity funding fell from £148m in the first half of 2025 to £47m a year later, a reduction of 68.3%. The number of first-time deals was 44, compared with a previous high of 73 in the first half of 2021.
Parkwalk argues that investors are increasingly able to finance established spinouts while newer companies face a more difficult route from laboratory research to an investable enterprise. Later-stage investment reached £760m, its strongest half-year since 2021, underlining how much of the current market is concentrated in businesses that have already demonstrated progress.
The wider investment profile has also changed over time. Average deal size more than doubled over the decade, from £3.57m to £7.24m. Larger rounds can support expensive research, specialised manufacturing and regulatory development. They do not, however, ensure that the next generation of spinouts can obtain the initial funding required to establish commercial viability.
International investors remain central to the market. Deals involving at least one overseas investor accounted for 86.1% of investment in the first half of 2026, the study finds. International buyers also represented 75% of spinout acquisitions in that period, although that figure measures acquisition activity rather than the nationality of the original research.
For the UK, the question is how much of the eventual commercial value remains connected to domestic research clusters and investors. Overseas capital can be essential to scale a British company, particularly in fields requiring significant investment before revenue becomes predictable. Yet limited domestic scale-up financing can leave founders dependent on international funding terms or potential buyers.
Geographic imbalance remains pronounced. The report estimates that nearly 80% of spinout investment since 2016 went to London, the South East and the East of England. Oxford-linked spinouts raised £5.39bn over the decade, compared with £3.99bn for Cambridge and substantially smaller totals in several northern university centres.
Parkwalk has called for greater certainty around the Enterprise Investment Scheme, which offers tax incentives to qualifying investors. Such a change might support some early-stage fundraising, although it would not independently resolve the need for specialist fund managers, commercially experienced teams and follow-on financing.
The first round of external equity is a critical step because it can finance proof-of-concept work, early hires and the transition from an academic research setting to an independent company. Prospective investors must assess technical risk without the revenue history available in more mature businesses. Specialist funds and universities can help by providing patient capital, commercial mentoring and access to intellectual property expertise. If fewer ventures receive that initial backing, a healthy market for established spinouts may be followed by a thinner pipeline of companies reaching later financing rounds several years from now.
The research portrays a market that can attract major international investment in established science businesses while leaving the earliest stage of company creation exposed. Future assessments will need to look beyond headline totals and examine how many new companies secure their first round and go on to raise growth capital.
You must be logged in to post a comment.